Substance P is Associated with the Development of Obesity, Chronic Inflammation and Type 2 Diabetes Mellitus

Abstract

Background: Substance P (SP) is an important neurotransmitter and is an important pathogenic factor in obesity. However, the relationships between the inflammatory cytokines interleukin-6 (IL-6), C reactive protein (CRP) and SP with obesity and type 2 diabetes mellitus (T2DM) are poorly understood.

Objective: We investigated the associations between SP, IL-6 and CRP with obesity and T2DM.

Subjects and Methods: The subjects comprised patients who underwent physical examinations at the First Affiliated Hospital of Harbin Medical University between January 2006 and December 2008. Overall, 156 subjects participated in this study, including 63 obese (BMI >25 kg/m²) subjects with T2DM, and 58 obese and 35 lean subjects without T2DM. Patient characteristics were collected from a health questionnaire form. Anthropometric measurements and fasting blood samples were assessed. SP, CRP, IL-6 and HOMA-IR were converted into log values.

Results: SP, IL-6, CRP and HOMA-IR were significantly higher (P<0.05) in obese T2DM subjects compared with obese and lean subjects without T2DM. All 3 parameters were significantly associated with other risk factors for diabetes, including BMI, blood pressure, plasma glucose and high-density lipoprotein levels. After adjusting for age, SP was significantly and positively correlated with BMI and logHOMA-IR (P≤0.05); correlation coefficients were higher in obese T2DM subjects than in lean or obese subjects without T2DM.

Conclusions: High levels of SP and IL-6 were significantly associated with obesity and risk factors for T2DM. Associations were of greatest in obese T2DM subjects. Obesity and T2DM show additive effects on the association between SP and BMI or logHOMA-IR.

Key words

C-reactive protein - diabetes - HOMA-IR - interleukin-6 - obesity - substance P

References

• 1 Alvaro G, Di Fabio R. Neurokinin 1 receptor antagonists – current prospects.  Curr Opin Drug Discov Devel. 2007;  10 (5) 613-621
• 2 American Diabetes Association. . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.  Diabetes Care. 1997;  20 (7) 1183-1197
• 3 Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars.  Science. 2005;  307 (5717) 1909-1914
• 4 Burdo JR, Chen Q, Calcutt NA. et al . The pathological interaction between diabetes and presymptomatic Alzheimer's disease.  Neurobiol Aging. 2009;  30 (12) 1910-1917
• 5 Chang MN, Leeman SE. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as Substance P.  J Biol Chem. 1970;  245 (18) 4784-4790
• 6 Cummings J, MacLellan A, Langdon SP. et al . Stability and in vitro metabolism of the mitogenic neuropeptide antagonists [D-Arg1,D-Phe5, D-Trp7,9, Leu11]-substance P and [Arg6, D-Trp7,9, MePhe8]-substance P (6-11) characterized by high-performance liquid chromatography.  J Pharm Biomed Anal. 1994;  12 (6) 811-819
• 7 de Almeida BB, Mathias MG, Portari GV. et al . Chronic acetonemia alters liver oxidative balance and lipid content in rats. A model of NASH?.  Exp Clin Endocrinol Diabetes. 2010;  118 (1) 61-63
• 8 Dietrich MO, Horvath TL. Feeding signals and brain circuitry.  Eur J Neurosci. 2009;  30 (9) 1688-1696
• 9 Fleischman A, Shoelson SE, Bernier R. et al . Salsalate improves glycemia and inflammatory parameters in obese young adults.  Diabetes Care. 2008;  31 (2) 289-294
• 10 Gustafson B. Adipose Tissue, Inflammation and Atherosclerosis.  J Atheroscler Thromb. 2010 Feb 3;  [Epub ahead of print]
• 11 Harrison S, Geppetti P. Substance P.  Int J Biochem Cell Biol. 2001;  33 (6) 555-576
• 12 International Diabetes Federation – Western Pacific Region. .Asian-Pacific Type 2 diabetes Policy Group. Type 2 Diabetes: Practical Targets and Treatments, 4th Edition 2005 Available at: http://www.idf.org/webdata/docs/T2D_practical_tt.pdf (Last accessed: April 13, 2010)
• 13 Karagiannides I, Kokkotou E, Tansky M. et al . Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes.  Proc Natl Acad Sci U S A. 2006;  103 (13) 5207-5212
• 14 Karagiannides I, Torres D, Tseng YH. et al . Substance P as a novel anti-obesity target.  Gastroenterology. 2008;  134 (3) 747-755
• 15 Koon HW, Zhao D, Zhan Y. et al . Substance P mediates antiapoptotic responses in human colonocytes by Akt activation.  Proc Natl Acad Sci U S A. 2007;  104 (6) 2013-2018
• 16 Joslin G, Krause JE, Hershey AD. et al . Amyloid-beta peptide, substance P, and bombesin bind to the serpin-enzyme complex receptor.  J Biol Chem. 1991;  266 (32) 21897-21902
• 17 Mather KJ, Funahashi T, Matsuzawa Y. et al . Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program.  Diabetes. 2008;  57 (4) 980-986
• 18 Miklossy J, Qing H, Radenovic A. et al . Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.  Neurobiol Aging. 2008. Oct 23;  [Epub ahead of print]
• 19 Percik R, Stumvoll M. Obesity and cancer.  Exp Clin Endocrinol Diabetes. 2009;  117 (10) 563-566
• 20 Pieri M, Amadoro G, Carunchio I. et al . SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels.  Neuropharmacology. 2010;  58 (1) 268-276
• 21 Quartara L, Maggi CA. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation.  Neuropeptides. 1997;  31 (6) 537-563
• 22 Ribeiro-da-Silva A, Hokfelt T. Neuroanatomical localisation of Substance P in the CNS and sensory neurons.  Neuropeptides. 2000;  34 (5) 256-271
• 23 Samy N, Hashim M, Sayed M. et al . Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index.  Dis Markers. 2009;  26 (4) 163-170
• 24 Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030.  Diabetes Res Clin Pract. 2010;  87 (1) 4-14
• 25 Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance.  Gastroenterology. 2007;  132 (6) 2169-2180
• 26 Takenouchi T, Munekata E. Trophic effects of substance P and beta-amyloid peptide on dibutyryl cyclic AMP-differentiated human leukemic (HL-60) cells.  Life Sci. 1995;  56 (26) PL479-PL484
• 27 Thorand B, Kolb H, Baumert J. et al . Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984–2002.  Diabetes. 2005;  54 (10) 2932-2938
• 28 Tian F, Luo R, Zhao Z. et al . Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes.  Exp Clin Endocrinol Diabetes. 2010;  118 (4) 258-265
• 29 Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease.  Lancet. 2005;  365 (9473) 1817-1820
• 30 World Health Organization. . Obesity and overweight.  2003;  Available at: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ (Last accessed: April 12, 2010)
• 31 World Health Organization – Western Pacific Region . The Asia-Pacific perspective: Redefining obesity and its treatment.  2000;  Available at: http://www.wpro.who.int/internet/resources.ashx/NUT/Redefining+obesity.pdf (Last accessed: April 26, 2010)

Correspondence